Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today that the first Alzheimer’s patient has been dosed in a Phase 1b clinical trial of CT1812 in mild to moderate Alzheimer’s disease.